clopidogrel + DWC202203

This is a combination product consisting of **clopidogrel**, a well-established oral antiplatelet agent that acts as a platelet aggregation inhibitor, and **DWC202203**, for which there is insufficient publicly available information to confirm its molecular identity, mechanism of action, or therapeutic intent. Clopidogrel is a prodrug that requires hepatic conversion to its active thiol metabolite, which irreversibly inhibits the P2Y12 subtype of adenosine diphosphate (ADP) receptor on the platelet surface, thereby preventing platelet activation and aggregation. This effect reduces the risk of myocardial infarction and stroke in at-risk patients[2][3][5]. The mechanism of action, indication, and modality for DWC202203 are unclear from available sources, and there are no references to this agent in major drug or clinical trial databases. Combination therapy with clopidogrel is typically used in cardiovascular and cerebrovascular risk reduction; any effect or therapeutic role of DWC202203 would depend on its nature, which remains undefined.

Other names

clopidogrel + DWC202203